US 12,257,247 B2
Targeted degradation of VAV1
Laura Ann McAllister, Basel (CH); Andreas Ritzen, Basel (CH); and Vladimiras Oleinikovas, Basel (CH)
Assigned to Monte Rosa Therapeutics AG, Basel (CH)
Filed by Monte Rosa Therapeutics AG, Basel (CH)
Filed on Apr. 11, 2024, as Appl. No. 18/633,272.
Application 18/633,272 is a continuation of application No. PCT/US2024/010733, filed on Jan. 8, 2024.
Claims priority of provisional application 63/437,951, filed on Jan. 9, 2023.
Prior Publication US 2024/0285604 A1, Aug. 29, 2024
Int. Cl. A61K 31/4545 (2006.01); A61P 1/04 (2006.01); A61P 19/02 (2006.01); A61P 37/06 (2006.01); C07D 401/10 (2006.01)
CPC A61K 31/4545 (2013.01) [A61P 1/04 (2018.01); A61P 19/02 (2018.01); A61P 37/06 (2018.01); C07D 401/10 (2013.01)] 12 Claims
OG exemplary drawing
 
1. A compound represented by the formula:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt or stereoisomer thereof.